Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto™ is an established brand in Canada currently available nationwide across several channels and expanding into new international markets. Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the medical cannabis patients’ journey. MyMedi.ca
is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens. Pharmaceutical pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are
in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders. Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part
of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.
Avicanna, Nick Hilborn, Chief Financial Officer, CFO, CPA CA, RHO Phyto, MyMedi.ca, Northern Green Canada Inc., Santa Marta Golden Hemp SAS, SMGH, cannabinoid pipeline, chronic pain, dermatology, neurological disorders
So Nick Hilborn is the new CFO… cool I guess.
I don’t even get why they’re talking about gummies and pharmacists? Like is this about medicine or just branding? Also “bilingual pharmacist-led” sounds like marketing to me.
Wait, the CFO shift and then they mention veterans and reimbursement… so like is Hilborn the one approving claims? That part feels backwards. And Aureus Santa Marta sounds like a coffee shop name, not an ingredient lol.
Avicanna has a whole pipeline for chronic pain and neurological disorders but the biggest headline is a financial leadership change? Feels like they’re hiding behind “MyMedi.ca” or whatever. Next they’ll say the transdermal stuff cures everything. I’m not saying it’s bad, I just don’t trust companies that expand into new international markets like that.